M
Mark T. Drayson
Researcher at University of Birmingham
Publications - 441
Citations - 21996
Mark T. Drayson is an academic researcher from University of Birmingham. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 69, co-authored 407 publications receiving 19337 citations. Previous affiliations of Mark T. Drayson include Queen Elizabeth Hospital Birmingham & University of Edinburgh.
Papers
More filters
Journal ArticleDOI
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Robert A. Kyle,J. Anthony Child,Kenneth C. Anderson,Bart Barlogie,Régis Bataille,William I. Bensinger,Joan Bladé,Mario Boccadoro,William S. Dalton,Meletios A. Dimopoulos,Benjamin Djulbegovic,Mark T. Drayson,Brian G.M. Durie,Thiery Facon,Rafael Fonseca,Gösta Gahrton,Philip R. Greipp,Jean Luc Harousseau,David P. Harrington,Mohamad A. Hussein,Douglas E. Joshua,Heinz Ludwig,Gareth J. Morgan,Martin M. Oken,R. L. Powles,Paul G. Richardson,David Roodman,Jesús F. San Miguel,Kazuyuki Shimizu,Chaim Shustik,Bhawna Sirohi,Pieter Sonneveld,Guido J Tricot,Ingemar Turesson,Brian G Van Ness,David H. Vesole,Donna M. Weber,Jan Westin,Keith Wheatley +38 more
TL;DR: The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations to facilitate comparison of therapeutic trial data.
Journal ArticleDOI
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
J. Anthony Child,Gareth J. Morgan,Faith E. Davies,Roger G. Owen,Sue E. Bell,Kim Hawkins,Julia Brown,Mark T. Drayson,Peter Selby +8 more
TL;DR: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age and trend toward a greater survival benefit in the group of patients with a poor prognosis.
Journal ArticleDOI
Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset.
TL;DR: The concept that normal pregnancy is associated with an elevation in the number of TReg cells which may be important in maintaining materno‐fetal tolerance is supported.
Journal ArticleDOI
Highly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and Urine
Arthur R. Bradwell,Hugh D. Carr-Smith,Graham P. Mead,Lian X. Tang,Paul J. Showell,Mark T. Drayson,Roger Drew +6 more
TL;DR: Sensitive, automated immunoassays for kappa and lambda FLC measurements in serum and urine that should facilitate the assessment of patients with light chain abnormalities are developed.
Journal ArticleDOI
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J. Morgan,Faith E. Davies,Walter M Gregory,Kim Cocks,Sue E. Bell,Alex J Szubert,Nuria Navarro-Coy,Mark T. Drayson,Roger G. Owen,Sylvia Feyler,A John Ashcroft,Fiona M. Ross,Jennifer Byrne,Huw Roddie,Claudius Rudin,Gordon Cook,Graham Jackson,J. Anthony Child +17 more
TL;DR: These findings support immediate treatment with zoledronic acid in patients with newly diagnosed multiple myeloma, not only for prevention of skeletal-related events, but also for potential antimyeloma benefits.